All Eyes On US Approval After Ipsen’s FOP Candidate Rejected By EU

Second Time Lucky?

The French firm’s palovarotene for fibrodysplasia ossificans progressiva received a thumbs down from the European Commission, but a positive advisory committee outcome on the other side of the pond bodes well for its second attempt at US approval.  

red cross graphic in hand
The EU Has Rejected The Drug After A CHMP Negative Opinion • Source: Shutterstock
Key Takeaways
  • The rejection follows on from a negative CHMP opinion issued in January.

  • Ipsen went against FDA advice and designed a single-armed pivotal trial for palovarotene.

  • A recent Adcomm meeting on the drug ended on a positive note despite some criticism.

After a controversial clinical development path, Ipsen SA’s palovarotene has been rejected in the EU for the treatment of the ultra-rare bone disorder fibrodysplasia ossificans progressiva (FOP), but an

FOP causes permanent new bone formation in the soft and connective tissues, a process known as heterotopic ossification (HO)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By 

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.